Repligen (RGEN) Earnings Date & Reports

Key Takeaways

• Repligen posted record third-quarter revenue of $209.3 million, up 10.9% year over year and slightly ahead of the roughly $207 million consensus estimate.
• Adjusted earnings per share (EPS) of $0.53 beat analyst expectations of $0.46, while organic revenue growth reached 12.5%.
• On a GAAP basis (generally accepted accounting principles), the company reported a net loss of $38.4 million, or $0.68 per share, driven by a $41 million intangible asset impairment charge.
• Management raised full-year 2026 guidance, with revenue now expected between $844 million and $852 million and adjusted EPS near $2.07 at the midpoint.
• Franchise performance was mixed: chromatography grew more than 50%, proteins more than 40%, and analytics 20%, while filtration declined 11%.
• For more context on this ticker's performance, you can explore Major News, Today's Price Move, Price Targets, and Forecast.
• For automated market insights, consider exploring Trending AI Robots.

Earnings Context and Why It Matters

Repligen is a leading supplier of bioprocessing technologies used to manufacture biological drugs, serving biopharmaceutical developers and contract development and manufacturing organizations (CDMOs). Its results are closely watched as a barometer of demand across the broader bioprocessing supply chain, which has been recovering from a post-pandemic inventory correction. A record revenue quarter and rising organic growth suggest that customer demand for consumables and services is firming, even as capital equipment purchases remain uneven. The quarter also carried an unusual GAAP wrinkle: a large non-cash intangible impairment charge tied to an older intellectual property agreement. For investors, the report highlights both improving end-market momentum and the accounting noise that can obscure underlying operating progress.

Reported Results

For the third quarter ended September 30, 2026, Repligen reported total revenue of $209.31 million, a 10.9% increase from $188.81 million a year earlier and modestly above the consensus estimate of about $206.75 million. Organic growth, which excludes acquisitions, divestitures, and foreign exchange, was 12.5%.

Adjusted (non-GAAP) diluted EPS came in at $0.53, topping the FactSet consensus of $0.46 by roughly 14.6%. Adjusted operating income rose 24% year over year to $33 million, and adjusted operating margin expanded 170 basis points to 15.9%. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached approximately $43.8 million, a 20.9% margin.

On a GAAP basis, results were weighed down by a $41 million non-cash intangible asset impairment charge related to an intellectual property license agreement. This contributed to a reported net loss of $38.4 million, or $0.68 per diluted share, versus net income of $14.9 million, or $0.26 per share, in the prior-year quarter.

Management also raised its full-year 2026 outlook, reflecting strength across the portfolio and the October 6 acquisition of BioLife. Revenue guidance was increased to a range of $844 million to $852 million, with BioLife expected to contribute roughly $24 million in the fourth quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and emerging opportunities far more efficiently than manual screening. For investors tracking companies like Repligen, it offers a structured way to identify comparable setups and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Investor response to the results appeared mixed. The company delivered a clear earnings beat on adjusted metrics and raised full-year guidance, which typically supports positive sentiment. However, the headline GAAP loss, driven by the sizable intangible impairment, introduced a layer of caution. Sentiment heading into the print had been constructive as bioprocessing demand gradually improved, and management's commentary about record capital equipment orders and strong China growth reinforced the narrative of a recovering end market. At the same time, the filtration segment's 11% decline, partly reflecting an anticipated headwind plus equipment delivery timing, remained a point of focus. Overall, the market's interpretation centered on the durability of consumables demand and the pace of capital equipment recovery rather than the one-time accounting charge.

Forward Outlook and Key Factors to Monitor

Following this report, investors are likely to focus on several forward-looking themes. First, guidance execution will matter: management now expects full-year revenue between $844 million and $852 million, with organic growth of 12% to 13%. The BioLife integration and its expected fourth-quarter contribution will be an early test of the company's cell therapy expansion strategy.

Second, the capital equipment cycle deserves close attention. Although equipment revenue declined in the quarter as deliveries shifted into 2027, orders grew by mid-teens and reached their highest quarterly level in five years. How quickly that backlog converts into recognized revenue will shape near-term growth visibility.

Third, margin trends remain important. Management indicated that the third quarter was expected to mark the low point for gross margin in 2026, and investors will watch whether product mix, pricing, and volume leverage support continued adjusted operating margin expansion.

Finally, regional dynamics, particularly China's greater than 40% growth, and the progression of consumables and services demand will be key indicators of underlying bioprocessing health as the industry continues its gradual recovery.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations